A Randomized, open-label, single dose, crossover phase I clinical study to compare the pharmacokinetic profiles and bactericidal activity of Zabofloxacin 183mg, 367mg and Levofloxacin 250mg after oral administration in healthy volunteer

Trial Profile

A Randomized, open-label, single dose, crossover phase I clinical study to compare the pharmacokinetic profiles and bactericidal activity of Zabofloxacin 183mg, 367mg and Levofloxacin 250mg after oral administration in healthy volunteer

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs Zabofloxacin (Primary) ; Levofloxacin
  • Indications Community-acquired pneumonia; Respiratory tract infections
  • Focus Pharmacokinetics
  • Sponsors Dong Wha Pharmaceutical
  • Most Recent Events

    • 26 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 11 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
    • 11 Feb 2015 Planned primary completion date changed from 1 Aug 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top